Analysis of fungal infections after CAR-T

On going projects

The DESCAR-T registry has been created at the request of the French Health Authorities to collect data on the efficacy and safety at both short- and long-term of all CAR-T cell therapies marketed in France.

Patients who receive CAR-Ts experience an increased risk of developing infections, including certain types of infections, such as invasive fungal infections. There is a need to better understand this adverse effect in order to offer the best care to patients developing or at risk of developing these infections.

An analysis project leveraging DESCAR-T data has been initiated by infectiologists and hematologists from Henri Mondor Hospital in Créteil. The objective is to provide a better description of these infections, their treatment, the profile of the patients experiencing these infections, and the potential benefit of preventive (prophylactic) treatments for patients with Non-Hodgkin B lymphoma. The registry data will be completed by data from patients’ medical records to specify some aspects related to the fungal infections studied. Statistical analyses will be performed by the LYSARC.

The analyses for this project will start in the course of the first semester of 2023.

To the patients that received CAR-T, especially for patients diagnosed with Non-Hodgkin B lymphoma, if you would like more information about the treatment of your data in this project or in the DESCAR-T Registry, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.